← Oncology Approval Tracker

FDA DECISION ·

Libtayo

cemiplimab-rwlc · Regeneron

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

First-line monotherapy for advanced non-small cell lung cancer with PD-L1 tumor proportion score of at least 50% by an FDA-approved test and without EGFR, ALK or ROS1 aberrations. This covers metastatic disease or locally advanced disease unsuitable for surgery or definitive chemoradiation.

LAMPGEN ANALYSIS

Why it matters

The original lung cancer indication is PD-L1-selected checkpoint monotherapy.

What research teams should watch

Retain the PD-L1 score, driver testing and confirmation of eligibility for definitive local therapy.

PRIMARY RECORDS

Sources